期刊
JACC-CARDIOVASCULAR INTERVENTIONS
卷 13, 期 2, 页码 219-231出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2019.08.015
关键词
patient selection; risk score; TAVR
资金
- National Institutes of Health T-32 training grant [5 T32 HL069749-14]
- Abbott Vascular
- Boston Scientific
- Patient-Centered Outcomes Research Institute
- American College of Cardiology
- Society of Thoracic Surgeons
- National Institutes of Health
- Food and Drug Administration (National Evaluation System for Health Technology)
- Edwards Lifesciences
- Medtronic
- Abbott
- Gore
- Abiomed
- Cardiovascular Systems Inc.
- CathWorks
- Siemens AG
- Philips
- ReCor Medical
OBJECTIVES This study sought to evaluate the ability of individual markers of frailty to predict outcomes after transcatheter aortic valve replacement (TAVR) and of their discriminatory value in different age groups. BACKGROUND Appropriate patient selection for TAVR remains a dilemma, especially among the most elderly and potentially frail. METHODS The study evaluated patients $65 years of age in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry, linked to Centers for Medicare and Medicaid administrative claims data, receiving elective TAVR from November 2011 to June 2016 (n = 36,242). Indices of frailty included anemia, albumin level, and 5-m walk speed. We performed Cox proportional hazards regression for 30-day and 1-year mortality, adjusting for risk factors known to be predictive of 30-day mortality in the Transcatheter Valve Therapy registry, as well as survival analysis. RESULTS These indices are independently associated with mortality at 30 days and 1 year and provide incremental value in risk stratification for mortality, with low albumin providing the largest value (hazard ratio: 1.52). Those with low albumin and slower walking speed had longer lengths of stay and higher rates of bleeding and readmission (p < 0.001). Those with anemia also had higher rates of bleeding, readmission, and subsequent myocardial infarction (p < 0.001). CONCLUSIONS This represents the largest study to date of the role of frailty indices after TAVR, further facilitating robust modeling and adjusting for a large number of confounders. These simple indices are easily attainable, and clinically relevant markers of frailty that may meaningfully stratify patients at risk for mortality after TAVR. (C) 2020 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据